Griffith & Werner Inc. Has $1.55 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Griffith & Werner Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,832 shares of the biopharmaceutical company’s stock after selling 604 shares during the quarter. Gilead Sciences comprises approximately 1.0% of Griffith & Werner Inc.’s holdings, making the stock its 29th largest position. Griffith & Werner Inc.’s holdings in Gilead Sciences were worth $1,550,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in Gilead Sciences in the 4th quarter worth approximately $1,789,254,000. FMR LLC increased its position in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. GAMMA Investing LLC increased its position in Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after buying an additional 2,532,070 shares during the period. Northern Trust Corp increased its position in Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Gilead Sciences in the 4th quarter worth approximately $207,340,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $112.46 on Friday. The stock’s fifty day simple moving average is $105.39 and its 200 day simple moving average is $101.56. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a market cap of $139.89 billion, a price-to-earnings ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Gilead Sciences’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.32) EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.81%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio is 66.53%.

Analysts Set New Price Targets

Several research analysts have commented on GILD shares. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Finally, Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 60,929 shares of company stock valued at $6,748,980 in the last 90 days. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.